section name header

Pronunciation

toe-poe-TEE-kan

Classifications

Therapeutic Classification: antineoplastics

Pharmacologic Classification: enzyme inhibitors

Indications

High Alert

Action

Therapeutic Effects:

Pharmacokinetics

Absorption: IV administration results in complete bioavailability. 40% absorbed following oral administration.

Distribution: Well distributed to tissues.

Metabolism/Excretion: Small amounts metabolized by the liver. 18–33% excreted in feces and 20–50% excreted in urine (primarily as metabolites).

Half-life: PO: 3–6 hr; IV: 2–3 hr.

Time/Action Profile

(effects on WBCs)

ROUTEONSETPEAKDURATION
POunknown1–2 hr24 hr
IVwithin days11 days7 days

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Derm: alopecia.

GI: abdominal pain, diarrhea, nausea, vomiting, liver enzymes, anorexia, constipation, stomatitis.

Hemat: anemia, leukopenia, thrombocytopenia.

MS: arthralgia.

Neuro: headache, fatigue, weakness.

Resp: dyspnea, ILD.

Interactions

Drug-Drug:

Route/Dosage

see Calculator

Renal Impairment

Renal Impairment

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Hycamtin